Background Cannabidiol (CBD), which is one major constituent of the Cannabis sativa plant,
has anti-seizure properties and does not produce euphoric or intrusive side effects. A plant …

Concomitant use of cannabis with other drugs may lead to cannabis–drug interactions,
mainly due to the pharmacokinetic mechanism involving the family of CYP450 isoenzymes …

Dravet syndrome is a severe developmental and epileptic encephalopathy characterised by
refractory seizures and cognitive dysfunction. The treatment is challenging, not least …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may lead to
coronavirus disease 2019 (COVID-19) which, in turn, may be associated with multiple organ …

Introduction In light of the widespread use of non-prescribed and prescribed cannabidiol, the
use of cannabidiol with other medications is likely, and this may result in drug interactions …

Introduction Pharmaceutically purified oral cannabidiol (CBD) has been recently approved
by the US Food and Drug Administration and European Medicines Agency as treatment of …

Background: Purified cannabidiol (CBD) was administered to highly refractory patients with
Dravet (DS) or Lennox–Gastaut (LGS) syndromes in an ongoing expanded access program …

Interest in using cannabis products for a medical purpose in children under the age of 18
years is increasing. There are many medical cannabis products available that can include …

Cannabis has been used for both recreational and medicinal purposes for more than 4
millennia. Cannabis has been studied in various medical disorders including neurological …

Introduction The safety and efficacy of a formulation high in cannabidiol (CBD) and low in∆ 9-
tetrahydrocannabinol (THC) to treat drug-resistant epilepsy have been examined previously …